News & Updates

Infants born to mothers with prepregnancy obesity are at risk of sudden unexpected infant death (SUID), with the risk increase commensurate with maternal BMI, according to a large US nationwide cohort study.

The antilipidemic drug fenofibrate averts or delays diabetic retinopathy (DR) in diabetes patients with early retinal changes in the LENS trial, potentially paving the way for the least invasive route of drug delivery in this population.

The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.

A triage led by a physiotherapist (PT) performs as reliably as a rheumatologist triage of referrals for joint pain, with significantly fewer patients with inflammatory arthritis (IA) needing an in-clinic visit, a recent study has shown.

Gut microbiota biomarkers show >90 percent sensitivity and specificity in diagnosing autism spectrum disorder (ASD). Gut microbiome modulation with a novel synbiotic formula, SCM06, may alleviate anxiety symptoms in children with ASD, according to researchers from the Chinese University of Hong Kong (CUHK).

An economic evaluation study by the University of Hong Kong (HKU) found treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) to be cost-effective compared with leflunomide in patients with rheumatoid arthritis (RA) who failed initial treatment with methotrexate (MTX).

Liver cancer is a major cause of death globally and in Hong Kong. Both first- and second-line treatment of the disease have evolved considerably over recent years, following the approval of immune checkpoint inhibitors (ICIs). At present, over half of hepatocellular carcinoma (HCC) patients require second-line treatment, yet data on therapies administered after immunotherapy are lacking. This article summarizes locally reported findings on use of cabozantinib and stereotactic body radiotherapy (SBRT) in HCC patients who progressed on immunotherapy.